Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure

Cardiovascular Pathology

Volumn 22, Issue 6, 2013, Pages 444-450

  Zhao, Dong Sheng ^a   Chen, Yan ^b   Jiang, Hui ^b   Lu, Jing Ping ^b   Zhang, Gang ^b   Geng, Jie ^b   Zhang, Qing ^a   Shen, Jian Hua ^c   Zhou, Xin ^b   Zhu, Wei ^b   Shan, Qi Jun ^b  

^a NANTONG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

Author keywords

Chronic heart failure; Fetus; Serum micrornas

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR; MICRORNA; MICRORNA 210; MICRORNA 30A; SODIUM; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CALCIUM SIGNALING; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FETUS; FETUS CIRCULATION; GENE EXPRESSION; HEART FAILURE; HUMAN; MALE; MIDDLE AGED; PREGNANT WOMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SODIUM ABSORPTION; UMBILICAL CORD BLOOD; UMBILICAL VEIN; UPREGULATION; VASCULAR SMOOTH MUSCLE; VENOUS BLOOD;

CHRONIC HEART FAILURE; FETUS; SERUM MICRORNAS;

ADULT; AGED; CASE-CONTROL STUDIES; CHINA; CHRONIC DISEASE; COMPUTATIONAL BIOLOGY; FEMALE; FETAL BLOOD; GENE REGULATORY NETWORKS; GENETIC MARKERS; HEART FAILURE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84893688067     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2013.04.001     Document Type: Article

References (35)

1. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008;105(6):2111-6.
2. Zhao Y R J, Li A, Vedantham V, Von Drehle M, Muth AN, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007:303-17.
3. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22(23):3242-54.
4. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009;119(9):2772-86.
5. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, Van Laake LW, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116(3):258-67.
6. Valadi H E K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007:654-9.
7. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100(3):416-24.
8. Van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006;103(48):18255-60.
9. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009;119(9):1263-71.
10. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007;170(6):1831-40.
11. Tijsen AJ, Creemers EE, Moerland PD, De Windt LJ, Van Der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010;106(6):1035-9.
12. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012;14(2):147-54.
13. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007;31(3):367-73.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105(30):10513-8.
15. Shen E, Diao X, Wei C, Wu Z, Zhang L, Hu B. MicroRNAs target gene and signaling pathway by bioinformatics analysis in the cardiac hypertrophy. Biochem Biophys Res Commun 2010;397(3):380-5.
16. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120(1):15-20.
17. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006;126(6):1203-17.
18. Tanabe M, Kanehisa M. Using the KEGG database resource. Curr Protoc Bioinformatics 2012 (Chapter 1: Unit 1):12.
19. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007;12(3-4):331-43.
20. Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 2010;9(6):1072-83.
21. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008;14(5):1340-8.
22. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008;7(2):255-64.
23. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010;116(9):2148-58.
24. Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers 2009;27(6):255-68.
25. Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke 2008;39(3):959-66.
26. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 2008;582(16):2397-401.
27. Biswas S, Roy S, Banerjee J, Hussain SR, Khanna S, Meenakshisundaram G, et al. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA 2010;107(15):6976-81.
28. Greco S, Fasanaro P, Castelvecchio S, D'Alessandra Y, Arcelli D, Di Donato M, et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012;61(6):1633-41.
29. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009;10(4):273-84.
30. Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010;5(4):e10345.
31. Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010;29(30):4362-8.
32. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009;8(17):2756-68.
33. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, Van Der Made I. miR-133 and miR-30 regulate connective tissue growth factor: implications for arole of microRNAs in myocardial matrix remodeling. Circ Res 2009;104(2):170-8 6p following 178.
34. Miller WL, Burnett JC, Hartman KA, Henle MP, Burritt MF, Jaffe AS. Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide. Am J Cardiol 2005;96(6):837-41.
35. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009;55(11):1944-9.